Previous 10 | Next 10 |
2023-04-26 21:05:20 ET Biomarin Pharmaceutical, Inc. (BMRN) Q1 2023 Earnings Conference Call April 26, 2023, 16:30 ET Company Participants Traci McCarty - Group VP, IR Jean-Jacques Bienaime - Chairman & CEO Jeffrey Ajer - Chief Commercial Officer Henry Fu...
2023-04-26 18:21:11 ET The following slide deck was published by BioMarin Pharmaceutical Inc. in conjunction with their 2023 Q1 earnings call. For further details see: BioMarin Pharmaceutical Inc. 2023 Q1 - Results - Earnings Call Presentation
2023-04-26 16:06:23 ET BioMarin Pharmaceutical press release ( NASDAQ: BMRN ): Q1 Non-GAAP EPS of $0.60 beats by $0.20 . Revenue of $596.4M (+14.8% Y/Y) beats by $26.01M . Growth of VOXZOGO ® Accelerated with Rapid Uptake in Japan and Brazil ...
BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues PR Newswire Growth of VOXZOGO ® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 Guidance Full-year 2023...
2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...
2023-04-22 04:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...
2023-04-19 09:35:00 ET Evercore ISI has initiated coverage of BridgeBio Pharma ( NASDAQ: BBIO ) with an outperform rating saying that two of its candidates are "potential blockbusters." The firm has a $40 price target (~164% upside based on Tuesday's close). Shares are...
2023-04-14 14:31:14 ET Summary BioMarin presents with attractive business economics that warrants a constructive view. The firm's revenue ramp looks steep and this could pull through to strong owner earnings to drive value for shareholders. My numbers point to attractive econo...
BioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , April 13, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bi...
2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...